Sanofi May Sell 200 Mature Drugs; Abbott, Mylan Potential Buyers

Source: Reuters

Jul 17, 2014

According to a 25-page internal document reviewed by Reuters, French drugmaker Sanofi has held talks with Abbott Labs, Mylan and private equity firms regarding the possible sale of an $8.5 billion portfolio of mature drugs.

The document indicated that Sanofi has been exploring multiple options - including potential sale, carve-out, or joint-venture - for mature drugs such as blood thinner Plavix, anti-epileptic Depakine and antibiotic Pyostacine.

A potential sale would minimize exposure to price cuts, reduce Sanofi's European manufacturing, and of course, free up cash.

According to Reuters, the document mentioned that that Pfizer, Japan's Otsuka and Teva were not interested in the drug portfolio, while talks with AstraZeneca and GSK were still pending.

Read the Reuters press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments